Technical Analysis for SLXN - Silexion Therapeutics Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | -16.99% | |
| Crossed Above 20 DMA | Bullish | -16.99% | |
| New Uptrend | Bullish | -16.99% | |
| Pocket Pivot | Bullish Swing Setup | -16.99% | |
| Volume Surge | Other | -16.99% | |
| Wide Range Bar | Range Expansion | -16.99% | |
| Wide Bands | Range Expansion | -16.99% | |
| Gapped Up | Strength | -16.99% | |
| Up 3 Days in a Row | Strength | -16.99% | |
| Upper Bollinger Band Touch | Strength | -16.99% |
| Alert | Time |
|---|---|
| 20 DMA Support | 37 minutes ago |
| 10 DMA Support | 37 minutes ago |
| Down 1 ATR | 37 minutes ago |
| Gapped Down (Full) | about 3 hours ago |
| 2x Volume Pace | about 3 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/12/2024
Silexion Therapeutics is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The company conducted a Phase 2a clinical trial in its first-generation product which showed a positive trend in comparison to the control of chemotherapy alone. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer.
Sector: Financial Services
Industry: Shell Companies
Keywords: Biotechnology Cancer Oncology Chemotherapy Pancreatic Cancer Oncogenes Solid Tumor Cancers Human Cancers Ras Gtpase Oncogene Locally Advanced Pancreatic Cancer
Classification
Sector: Financial Services
Industry: Shell Companies
Keywords: Biotechnology Cancer Oncology Chemotherapy Pancreatic Cancer Oncogenes Solid Tumor Cancers Human Cancers Ras Gtpase Oncogene Locally Advanced Pancreatic Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.5576 |
| 52 Week Low | 0.2097 |
| Average Volume | 6,497,871 |
| 200-Day Moving Average | 7.60 |
| 50-Day Moving Average | 0.44 |
| 20-Day Moving Average | 0.27 |
| 10-Day Moving Average | 0.25 |
| Average True Range | 0.07 |
| RSI (14) | 44.13 |
| ADX | 37.41 |
| +DI | 35.49 |
| -DI | 23.87 |
| Chandelier Exit (Long, 3 ATRs) | 0.26 |
| Chandelier Exit (Short, 3 ATRs) | 0.41 |
| Upper Bollinger Bands | 0.34 |
| Lower Bollinger Band | 0.20 |
| Percent B (%b) | 0.98 |
| BandWidth | 50.41 |
| MACD Line | -0.11 |
| MACD Signal Line | -0.15 |
| MACD Histogram | 0.0447 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.61 | ||||
| Resistance 3 (R3) | 0.62 | 0.54 | 0.56 | ||
| Resistance 2 (R2) | 0.54 | 0.47 | 0.54 | 0.55 | |
| Resistance 1 (R1) | 0.44 | 0.43 | 0.40 | 0.43 | 0.53 |
| Pivot Point | 0.36 | 0.36 | 0.34 | 0.35 | 0.36 |
| Support 1 (S1) | 0.25 | 0.29 | 0.21 | 0.24 | 0.13 |
| Support 2 (S2) | 0.18 | 0.25 | 0.17 | 0.12 | |
| Support 3 (S3) | 0.07 | 0.18 | 0.10 | ||
| Support 4 (S4) | 0.06 |
